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ABSTRACT 
OBJECTIVES: To assess the budget impact of restricting inappropriate inhaled corticosteroids (ICS) use according 
to the international Chronic Obstructive Lung Disease (GOLD)-guidelines indication for ICS use in the Chronic 
Obstructive Pulmonary Disease (COPD)-population, taking The Netherlands as a reference case. 
METHODS: A budget impact model was developed and closely aligned with the ISPOR best practice guidelines. The 
model estimates the impact of pharmacologic COPD maintenance treatments on clinical events (exacerbations and 
pneumonias) and associated healthcare utilization & costs. Current treatment mix included all maintenance treatments 
including long-acting muscarinic antagonists (LAMA), long-acting β2-agonists (LABA), LABA/ICS, LABA/LAMA, 
and triple therapy (LABA/LAMA/ICS). We modelled a situation where 25% of patients would use ICS-containing 
treatments and compared this to the current Dutch situation with 60% ICS use. A 5-year time horizon with a Dutch 
health care payer’s perspective was used. In sensitivity analyses, a range of values for absolute ICS reduction (20-
40%), relative risks of exacerbations and pneumonia events, and other input parameters were explored. 
RESULTS: Over a period of 5 years, the new treatment mix with GOLD guideline recommended ICS and 
LABA/LAMA use resulted in potential avoidance of 17,405 exacerbations, 11,984 pneumonias and accompanied 
savings of €84 million in the base-case scenario. Savings were consistent in various sensitivity analyses, indicating 
cost savings between €30 and €200 million.  
CONCLUSION: Reducing inappropriate ICS use and increased use of LABA/LAMA in COPD patients could result 




i. What is already known about the topic? Unnecessary use of inhaled corticosteroids (ICS) in patients with chronic
obstructive pulmonary disease (COPD) patients is prevalent and associated with potentially avoidable adverse drug 
reactions, yet its economic impact is unknown.  
ii. What does the paper add to existing knowledge? Tailoring ICS use to the COPD population indicated by
international GOLD guidelines can result in significant clinical and economic benefits on a Dutch national level. 
iii. What insights does the paper provide for informing health care-related decision making? Reducing ICS use
in patients with COPD has substantial budget impact and is mainly driven by avoidance of costly ICS adverse drug 
reactions. Careful targeting of ICS to the COPD population in need and active deprescribing in current over-users 
should be encouraged not only from a clinical, but also economic perspective. 
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is “a common, preventable and treatable disease that is characterized 
by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually 
by significant exposure to noxious particles or gases”.1
Worldwide, over 174 million patients suffer from COPD, causing 3.2 million deaths in 2015.2,3 In the Netherlands, 
more than half a million patients are suffering from COPD, with a considerable impact on the Dutch national health 
budget: over  €1 billion in 2015.4–7 Notably, costs for COPD mostly involve hospitalizations, medication, nursing home 
care, and productivity losses.8,9 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines make use of the “ABCD 
classification” for categorizing patients and selecting treatment.1 Symptoms and exacerbation history are used in 
determining the severity of COPD and the recommended medication. In GOLD A patients, (short or long-acting) 
bronchodilators are indicated, while in GOLD B patients, a long-acting muscarinic antagonist (LAMA) or a long-
acting β2-agonist (LABA) is recommended. In patients with GOLD C a LAMA is recommended and in GOLD D, that 
is, symptomatic patients who experience two or more moderate exacerbations (or one severe exacerbation) within a 
year and high blood eosinophil counts, inhaled corticosteroids (ICS) can be considered.1  
ICS have been shown to reduce exacerbations in various trials and can be administered next to a LAMA or LABA, or 
as part of fixed-dose combination inhaler together with a LABA or triple therapy (LAMA/LABA/ICS).10–17 However, 
ICS can also cause some serious adverse drug reactions(ADRs), such as pneumonia, dysregulated diabetes control and 
osteoporosis, as well as less serious but still significant local ADRs, such as oropharyngeal candidiasis, pharyngeal 
discomfort, cough and hoarseness. 18–23 In recent years, the mere use of LAMA/LABA combination therapy (i.e. 
without ICS) in COPD has been shown beneficial.10,15,24 To reflect this new evidence, the GOLD guidelines have been 
updated and recommend careful consideration of clinical benefits versus risks regarding ICS use.1 
Despite recommendations of conservative use of ICS in recent guidelines, in real-life, ICS are still used in many COPD 
patients that do not meet the aforementioned criteria.25–28 This non-adherence to COPD guidelines may not only result 
in potential side effects, but may also have economic consequences, although the latter has not been researched to date. 
Notably, a recent systematic review on COPD cost-effectiveness studies identified the incorporation of ADRs in 
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economic models, such as those arising from ICS, as an unmet need in COPD cost research.29 In addition, few budget 
impact analyses (BIAs) of COPD treatments have been published to date.29–31 
The objective of this study was to assess the budget impact of following the GOLD COPD guideline recommendations 
regarding ICS prescription, taking the Netherlands as a reference case.  
METHODS 
Study design 
A BIA was performed following the ISPOR Task Force Report, BIA-Principles of Good Practice designed within the 
context of an Excel-based cost-calculator model.32,33 The cost-calculator enables the calculation of the impact of 
different pharmacologic COPD maintenance treatments on clinical respiratory events (exacerbations, pneumonias) and 
associated healthcare resource utilization – in this context, respiratory events are calculated using the relative risks 
(RR) associated with each treatment group.  A brief review of the key elements in the ISPOR BIA-Principles of Good 
Practice is presented in Supplementary table 1, with an indication where we included its specific segments in our 
analysis. The model specifics are described in the following sections. 
Patient population 
The population considered in this analysis consists of COPD patients belonging to GOLD B, C and D classes, the 
population that may eligible for ICS treatment. As data on treatment use is not available per GOLD A-D class for the 
Netherlands, no stratification was possible for the GOLD classes in the model. GOLD A patients are excluded because 
there is no clinical benefit in treating them with ICS in clinical practice.1,25,34 Estimations of the total number of Dutch 
patients belonging to this population were taken from Dutch national published sources and reported in Table 1.35,36 
The size and growth of the Dutch COPD population was taken from the health exploration report of the Dutch public 
health institute (RIVM), which estimated the trends in morbidity and mortality of COPD for the next decades, primarily 
using primary care diagnostic data.6   
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Intervention mix 
The intervention considered in this model is pharmacological COPD maintenance treatment, with the current treatment 
mix for the COPD population including LAMA, LABA/ICS, LAMA/LABA, LAMA/LABA/ICS and other. 
LAMA/LABA/ICS was recently launched as fixed-dose “triple therapy” in the Netherlands.37 We assumed patients on 
other medication were using LABA therapy. 
We estimated market shares for the current maintenance treatment mix from national public sources, which we adjusted 
for the situation in 2017 by extrapolating market trends.17,38 The current percentage of patients using ICS-containing 
regimens was 60.2%. The market share for the triple therapy was estimated at 38.4% based on the concurrent use of 
LABA/ICS and LAMA. Similarly, a UK real-world study showed a proportion of 32% patients using triple therapy.39 
In the new intervention mix, 25% of GOLD B-D patients was assumed to be remaining on ICS therapy, in line with 
the percentage of COPD patients with GOLD criteria for ICS use. This was achieved by switching 75% of LABA/ICS 
users and 50% of LABA/LAMA/ICS users to LABA/LAMA treatment. Indeed, in the most recent guidelines, GOLD 
recommends ICS explicitly in patients with high (>300 cells/mm3) eosinophil counts, which is present in +/-20% of 
the COPD population.1,40,41 Yet, to also account for other risk groups where ICS may be beneficial (e.g. frequent 
exacerbators, asthma-overlap.1,40–45), we considered a slightly higher percentage of ICS (i.e. 25%) in the new treatment 
mix. Note that these additional criteria could partly overlap (e.g. those COPD patients with high eosinophils may also 
have asthma overlap and have better ICS response in preventing exacerbations). Given the uncertainty around this 
conservative estimate, this assumption of 25% was extensively explored in sensitivity analyses (see later section). 
 
Time horizon  
A five year time horizon was used, in line with relevant planning horizons of Dutch policy makers, and ISPOR BIA-
Principles of Good Practice.32 Results are presented annually, starting from the year 2017, up to 2021. No discounting 
was applied.32  
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Perspective 
This BIA was performed from a Dutch health care payer’s perspective. This choice implicates inclusion of only direct 
health care costs; i.e. medications, hospitalizations, emergency room visits and ambulatory visits. Given the BIA 
guideline recommendation as well as the scarcity of data on impact on indirect costs (e.g. work productivity losses), 
these were not considered.32 
Analytic framework description  
The population GOLD B-D patients entering the cost calculator concerns all COPD patients using LAMA, 
LAMA/LABA, LABA/ICS, LAMA/LABA/ICS or other. The graphical description of the model structure is shown in 
Figure 1. The distribution of the population is given per treatment group. Costs inputs concern the pharmacological 
treatment costs, moderate and severe exacerbations, pneumonia, and diabetes-related events. Incidence rates of these 
events are stable across the five-year time horizon, although the actual number of events varies due to the changing 
exacerbation history and the in- and efflux of patients in the model. Notably, given the limited amount of data for 
diabetes-related hospitalizations, as well as their low occurrence (0.1-1%), these events were excluded from the base-
case and only assessed in an alternative scenario analysis.46 Given the limited body of evidence that suggests a 
difference in cardiovascular events between the different included treatment options, these were excluded from the 
model. 47–49 Ergo, clinical events included in the base-case only concerned pneumonias and exacerbations. 
Figure 1: Model flow chart 
Inputs and data sources 
All model input data are provided in Table 1. National Dutch data on COPD was identified through a keywords 
literature search in Medline (PubMed) and Embase. In addition, Dutch health related online sources were searched for 
relevant data. For all imputed costs we used Dutch data, and values given in price levels different from 2017 were 
inflated accordingly. 35,50,51 
The patient population size was based on national data sources and was extrapolated to reflect the COPD population 
over the period 2017 to 2021. Incidence and mortality estimates were already included in the extrapolated population 
numbers.4 To reflect the Dutch patient group belonging to GOLD B-D, we considered 72% of the total diagnosed 
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COPD population, as published in a national report that labels 28% as GOLD A.36 Input data for exacerbations 10,31,52–
55, pneumonia 21,51,56 and diabetes-related hospitalizations 23,56,57 were based on published data. Complication rates and 
cost calculations for exacerbations, pneumonias and diabetes are specified in the next sub- sections.  
Exacerbations  
LAMA/LABA users with no prior exacerbations were the reference case and RRs were estimated as compared to that 
group. For the base-case, RR data were derived from recent meta-analyses, comparing LAMA/LABA maintenance 
therapy to triple therapy58, LABA/ICS59 and LAMA monotherapy48. We assumed equal RRs across populations 
belonging to GOLD B-D.52   
Absolute annual exacerbation risk was estimated using risk of any exacerbation for GOLD B patients in the TONADO 
trial (39.4%).55 Additionally  the rates were used of moderate (78%) and severe (16%) exacerbations within the GOLD 
B/C sub-population of LAMA/LABA users with fewer than two exacerbations.55,60 This resulted in an annual absolute 
risk of 31% for moderate, and 6% for severe exacerbations (Table 1).  
Exacerbation history was assumed to have equal impact on both moderate and severe exacerbation risk. At baseline, 
we assumed equal exacerbation frequency proportions across the therapeutic options, resulting in 53% of patients with 
no exacerbations, 25% of patients with one exacerbation and 22% of patients with two or more exacerbations.52 
Exacerbation rates were dependent on absolute annual risk, exacerbation history and type of maintenance therapy 
used.31 
Pneumonia 
Pneumonia event risks were based on a meta-analysis of five recent trials comparing the pneumonia rates of 
LAMA/LABA users and LAMA/LABA/ICS users.58 We used a pneumonia rate of 4.7% in the control group and 
added a RR of 1.31 for ICS users.21,58  
Diabetes  
Data on risk for diabetes-related hospitalizations were derived from a cohort study of COPD patients with comorbid 
type II diabetes.23 We used the Dutch national prevalence of 20.9% COPD patients having diabetes (Table 1).57 Primary 
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care and medication costs, such as General Practitioner (GP) visits and a faster progression to insulin treatment, were 
not considered.23  
Costs inputs 
The annual costs of pharmacological treatments were calculated using Dutch national real-world reimbursement data, 
reflecting the average of all users within each drug class in the Netherlands for the year 2017.17 Event costs for 
exacerbations were based on previously published cost estimations, considering both moderate and severe 
exacerbations using weighted averages for resource use, ranging from hospitalizations to prescribed antibiotics and/or 
oral corticosteroids in the GP setting.31,61 Per event costs for pneumonia were calculated as a proportion of inpatient 
(28%) and outpatient (72%) events51, using Dutch open data of reimbursed costs in the healthcare system (open DIS 
data).56 Diabetes-related hospitalizations were calculated similarly; a weighted average was calculated for one 
hospitalization, taking into account the length of stay.56 
Table 1: Input data for the BIA model 
Analyses 
Using the cost calculator, we assessed the budget impact for the future treatment mix scenario with reduced use of 
ICS.  
Therapy prices were assumed to be subject to an annual reduction of 3% across all therapeutic options. 64  
Uncertainty and scenario analyses 
As evidence on the clinical effectiveness regarding exacerbation reduction and pneumonia risk of LABA/LAMA 
compared to triple therapy and LABA/ICS varies, we performed a sensitivity analysis taking into account a range of 
RRs and included these in separate figures; the point estimates of various clinical trials were included in the figures as 
well. 
Additionally, various key model inputs were varied and presented in a tornado diagram. This included scenarios where 
the percentage of patients remaining on ICS treatment was altered to both 20%, 30% and 40%; scenarios where only 
10
LABA/ICS or only LAMA/LABA/ICS use was reduced; and scenarios where the total COPD population was assumed 




When reducing ICS use within the Dutch COPD GOLD B-D population to 25% and increasing the use of 
LABA/LAMA therapy, both the number of exacerbations and pneumonia events decreased. Over a five-year period, 
the number of exacerbations decreased from 1,796,385 to 1,778,980, i.e. a decrease of 17,405 exacerbations or around 
9 exacerbations per day. The number of pneumonia events was lowered by 11,984 (from 129,034 to 117,050) over 
five years or around 6 daily occurrences of pneumonia. The clinical impact of prevented exacerbations and pneumonia 
events by appropriate ICS use is displayed in Figure 2; the disaggregated numbers of events are given in Supplementary 
table 2. 
Economic impact 
The new treatment mix, with reduced ICS use, resulted in lower budget impact compared to the 2017 intervention mix 
(Figure 2). Total costs for the 2017 intervention mix were estimated at €596 million and in the new mix at €579 million, 
with corresponding numbers for the whole 5-year follow-up period of €3.01 and €2.93 billion respectively. As such, 
the total 5-year savings are estimated at €84 million, i.e. around 3% of the total COPD costs. A complete overview of 
the disaggregated annual costs and savings are given in Supplementary table 3.  
Figure 2 shows the economic effects of the new intervention mix scenario to the budget impact, associated with 
pharmacological treatment, exacerbations and pneumonia. The reduction in pharmacological treatment costs in the 
new intervention mix scenario has the largest impact on COPD spending, followed by the costs associated with 
pneumonia. 
Figure 2 – Budget impact of inhaled corticosteroid reduction in COPD patients, presented by total and 
disaggregated cost savings over a 5-year follow-up 
Sensitivity analyses 
Figure 3 shows the effects of varying the RRs for exacerbations of LABA/LAMA/ICS and LABA/ICS, with 
LABA/LAMA as the reference on the budget impact, including the means of a variety of relevant trials. In all 
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alternative scenarios, limiting ICS use resulted in cost savings, even when data from the trial that showed the largest 
benefit for triple therapy, IMPACT, was used.11 Only at RRs for exacerbations lower than 0.7, additional costs will 
occur. For LABA/ICS compared to LABA/LAMA, the RR would have to drop below 1 before the new intervention 
mix would yield additional costs, but this is highly unlikely, considering the evidence from clinical trials.10,16,59 If the 
most conservative available evidence is used, i.e. the IMPACT trial for LABA/LAMA vs. triple therapy and the 
FLAME trial for LABA/LAMA vs. LABA/ICS, the budget impact still results in net cost savings of €30 million.10,11 
Using the least conservative numbers, i.e. the WISDOM and LANTERN trials, results in total net savings of €200 
million.15,16 The effect of the RRs of pneumonia caused by ICS-use is shown in Figure 4. For the whole range of RRs 
considered, the budget impact remains cost-saving. 
Figure 3 – Sensitivity analysis detailing the effect of varying the relative risk of exacerbations 
(LAMA/LABA/ICS vs. LABA/LAMA and LABA/ICS vs. LABA/LAMA) on the 5-year budget impact of 
appropriate inhaled corticosteroids use in COPD patients, including the point estimate of various clinical 
trials10–16 IMPACT: Informing the Pathway of COPD Treatment trial; TRIBUTE: Extrafine inhaled triple therapy 
versus dual bronchodilator therapy in chronic obstructive pulmonary disease trial; OPTIMAL: Tiotropium in 
combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary 
disease trial; SUNSET: Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with 
Chronic Obstructive Pulmonary Disease trial; WISDOM: Withdrawal of Inhaled Steroids during Optimized 
Bronchodilator Management trial; FLAME: Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD 
trial; LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD 
trial. 
Figure 4 – Sensitivity analysis detailing the effect of varying the relative risk of pneumonia (ICS use vs. non-
ICS use) on the 5-year budget impact of appropriate inhaled corticosteroids use in COPD patients, including 
the point estimates of various trials11–15 IMPACT: Informing the Pathway of COPD Treatment trial; TRIBUTE: 
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease trial; 
OPTIMAL: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic 
obstructive pulmonary disease trial; SUNSET: Long-Term Triple Therapy De-escalation to 
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Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease trial; WISDOM: Withdrawal 
of Inhaled Steroids during Optimized Bronchodilator Management trial. 
 
Figure 5 shows the various alternative scenario analyses. The alternative scenario with diabetes-related hospitalizations 
being included resulted in 2,591 avoided hospitalizations in five years, corresponding to €10 million of extra savings 
in 5 years. The savings of only reducing either triple therapy or LABA/ICS therapy separately are comparable, both 
around €42 million. Reducing or increasing the COPD population, also reduces or increases the budget savings. The 
ICS-use reduction impacts the model considerably, if 40% of GOLD B-D patients remain on ICS, the total 5-year 
savings decrease to €47 million, or €71 million for 30%; if 20% of patients remain on ICS, the savings increase to €95 
million. 
Figure 5 - Tornado diagram representing the 5-year savings achieved by reducing ICS-containing regimens in 
COPD in different scenarios. LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonists; ICS, 





Reducing the use of ICS-containing treatments, while increasing the LABA/LAMA use in COPD patients in the 
Netherlands, as indicated by the GOLD guidelines, could lead to cost savings of €84 million over a period of five 
years, while reducing the number of exacerbations by 17,405 and pneumonia-related events by 11,984. The main 
drivers for budget impact were lower pharmacological treatment costs and costs associated with avoided exacerbations 
and pneumonia events. 
Interpretation 
A recent Dutch budget impact study, focusing on the introduction of LABA/LAMA therapy, estimated the total annual 
COPD costs for the period 2015-2019 to increase from €489 to €663 million, considering costs for medications, 
management and exacerbations.31 Our annual estimations for the COPD budget in the period from 2017 to 2021 ranged 
from €580 to €610 million which seem in line with these previous projections.7 The new intervention mix with reduced 
ICS use under base-case assumptions resulted in cost-savings within the COPD budget of around 3% (annually and 
over 5 years). The total COPD budget, which currently accounts for about 0.6% of healthcare spending in the 
Netherlands, could stay flat or even decline in the coming years.35 Compared to earlier Dutch COPD budget 
estimations, our estimations are similar. 7,31 However, all budget estimates were based on slightly different 
methodologies and costs categories. Unlike previous publications, we considered ADR-related costs. 7,31 Additionally, 
differences in total expenses can be explained by the year of calculation, and the total size of the COPD population, 
which has increased considerably in recent years.6,7,36   
Due to a lack of previous publications focusing on the economic impact of ICS reduction, we were not able to compare 
our results. Yet, recent clinical evidence supports our results.24 Indeed, studies showed a decreased number of 
exacerbations and pneumonia events in patients who switched from LABA/ICS to LABA/LAMA.59,65 Another two 
studies comparing LABA/ICS with LABA/LAMA showed comparable safety profiles and higher incidence of 
pneumonia in the LABA/ICS treated patients.66,67 Furthermore, a Swedish study demonstrated lower costs and better 
outcomes when patients were using LABA/LAMA vs LABA/ICS.68 
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An older meta-analysis comparing LABA/LAMA and LABA/ICS, not used in our model study, showed a reduction 
in the incidence of pneumonia (8%) with use of LABA/LAMA.69 Our results are quite close with a 9% reduction of 
pneumonia events. This small difference may be caused by our consideration of all four available LABA/ICS treatment 
options in the Netherlands (salmeterol/fluticasone; formoterol/budesonide; formoterol/beclomethasone and 
vilanterol/fluticasone), while the meta-analysis considered only salmeterol/ fluticasone.  
Strengths and limitations 
To our knowledge, this is the first BIA considering the budget impact of reducing ICS-use in patients with COPD. 
This BIA complied with ISPOR’s BIA-Principles of Good Practice with respect to the reporting format and content.32 
The time horizon we used is in line with both ISPOR’s recommendations as well as relevant planning horizons of 
Dutch policy makers and Dutch guideline for economic evaluations in healthcare.50 
While the effects of additional ICS treatment vary between clinical trials, our results seem robust to these variations, 
as the reduction in ICS use remained cost-saving, independent of the clinical trial used. This was also the case when 
we reduced the rate of pneumonia events caused by ICS use. 
A limitation of this study is the uncertainty regarding the COPD population in the Netherlands. While most estimations 
are within the same range, these estimates are usually based on primary care diagnosis codes.57 Some patients with a 
COPD coding may not have spirometry confirmed COPD, which is the gold standard for proper diagnosis.4,6,7,36,70 
Notably, relying on COPD codes only may result in misclassified patients, underdiagnosis or overdiagnosis. We were 
also not able to incorporate the GOLD classes separately, due to a lack of detailed data on specific event rates and RRs 
per GOLD class. Additionally, there is some uncertainty on the percentage that benefits from remaining on ICS 
treatment, as data on the demographics and associated treatment regimes in the Netherlands of specific subgroups are 
not currently available, such as the proportion of patients with asthma or blood eosinophil counts (>300 cells/mm3).40,41 
The sensitivity analysis shows a considerable impact of the proportion of patients that continues to use ICS treatment 
on the budget impact difference; with a 5% decrease or increase of this proportion resulting in around a 15% increased 
or decreased budget impact difference respectively. 
16
Exacerbation history was assumed to be the same across the various treatment options, although we would suspect 
patients with triple therapy to have had more exacerbations in the past, as compared to e.g. LAMA monotherapy users. 
This marks a limitation in our analysis, as we were unable to find the necessary data to incorporate this difference in 
our analysis.  
Lastly, while this study mainly focused on the ADRs of ICS-treatments, non-ICS containing regimens such as single 
or dual bronchodilators could also give rise to ADRs, mainly in the cardiovascular area. According to a recent meta-
analysis, possible ADRs were atrial fibrillation (0.39%), myocardial infarction (0.27%), and coronary artery disease 
(0.26%).71 Several meta-analyses have been published that looked into the cardiovascular effects of COPD inhalation 
treatment, but event rates were low and significant differences between treatment options have not been found.47–49 
While this might impact absolute budget impact, the relative budget impact is not expected to be affected by this, 
considering there would be no difference caused by changing prescribing behaviour of ICS especially as these are 
usually prescribed in fixed-dose combination with LABA. Less serious ADRs, such as oropharyngeal candidiasis, 
pharyngeal discomfort, cough and hoarseness were also not included in the analysis, due to the minimal economic 
impact. 
Implications for practice and policy 
Given the substantial clinical and economic savings that could be achieved from restricting ICS use to the guidelines-
indicated COPD population, we recommend careful targeting of ICS to the COPD population in need and active 
deprescribing in current over-users should be encouraged. [1] Furthermore, exploring the reasons for inappropriate use 
of ICS treatments in real-life may be beneficial to identify strategies to stimulate shifts to non-ICS treatments. Still, 
improvements can be made in the adherence to the COPD guidelines by doctors: a Dutch study reported inappropriate 
prescribing for ICS treatments in 30% of COPD patients.72 Studies from the United Kingdom reported inappropriate 
ICS prescribing in 25% and 43% of COPD patients. 26,73 Similarly, an Australian study indicated 44% inappropriate 
use of ICS treatments.74  
Preventing ICS overuse in COPD patients could be achieved by improved education of healthcare professionals, better 
promotion of  therapy guidelines and improved diagnostic tools.  
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Conclusions 
Reducing inappropriate ICS use and increased use of LABA/LAMA in COPD patients could result in a reduction of 
exacerbations and pneumonias, corresponding with a reduction in total costs for COPD in the Netherlands.  
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Tables 
Table 1: Input data for the BIA model 
Population input data (2017) Population 
Size 
Source 
COPD population in the Netherlands 
Annual growth of COPD population 
Eligible population GOLD B-D (% of 







Market shares of treatment types 




Other (LABA): 6.6% 
17,38




Other (LABA): 6.6% 
Cost inputs Costs (€, 2017) 





















Diabetes-related hospitalizations 3512 
56
Clinical inputs Risk (per year) 
Exacerbations Absolute exacerbation risk 
Moderate: 0.31 
Severe: 0.06 
Relative risk by therapy  




Relative risk by exacerbation history 
No prior exacerbation: 1 
1 prior exacerbation: 2.55 








Relative risk ICS users 
Location of treatment 
Baseline (non-ICS users): 4.7%; 
RR (ICS users) : 1.31 
21
59
Outpatient: 72% ; Inpatient: 28% 51
Diabetes-related hospitalizations 
Prevalence in COPD patients 
Non-ICS users 4.5% 
ICS users: 6.0% 
23
27
20.9%  57 
COPD, Chronic Obstructive Pulmonary Disease; GOLD, The Global Initiative for Chronic Obstructive Lung Disease; 
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Clear and into a relation with the study perspectives. 
Info about disease prevalence, incidence, severity, disease 
progression, undiagnosed or undertreated cases and relevant 
risk factors. 
Eligible population, existing management options and efficacy 
and safety. 
Description on previous BIA for different intervention, 





Design Cost calculator (preferred approach), condition-specific cohort 






Eligible population for the new intervention (estimation on 
local coverage, open population-entering leaving rates, 
proportion of subgroups-if relevant). 
Recommended data sources: budget holder’s data, national or 
reginal data. 
Use and characteristics (indication, dose, efficacy, adverse 
events, and adherence) of the current and expected 
intervention mix (rates in tables describing the intervention 
mix). 
Recommended data sources, uptake rate and costs for  
current Intervention mix: budget’s holder data or published info 
form registries, claims databases, local surveys, market 
research, secondary sources; uptake rate to be based on past 
changes, market research or clinical expert opinion; costs 
based on actual cost on the intervention for the budget holder 
(including discounts, rebates), administration and monitoring 
costs (local unit costs, or product labels and publications), and 
side effects/complications managing/withdrawal  costs (rates 
form labels, and cost from published data or develop 
algorithms in consultations with physicians from the treatment 
field. 
new intervention mix: data from another jurisdiction where 
introduced or estimates of market share from the producer, or 
extrapolation on similar product diffusion in the budget 
holder’s settings;  and side effects/complications 
managing/withdrawal  costs (rates form labels, and cost from 
published data or develop algorithms in consultations with 









Presented and justified. 
Common period 1-5 years. 
Clear inclusion of cost categories and intended audience. 
Recommended-Budget holder perspective. 
Complete description of the model structure as well as being 
graphically presented (flow diagram). 
Input values and alternative scenarios. 
Description of any computations/transformations with 
assessment of straightness and weakness, as well as selection 
criteria for the literature inputs. 








Description of the calculations and justification of the choice of 
the scenarios. Recommendation: indirect cost should not be 
included; no discounting. 
Described and justified. Disaggregated presentation BIA for 
each budget period from the time horizon. 
Relevant: parameter (efficacy of current and new intervention) 
and structural (changes in expected intervention patterns) 







Table displaying change in use for each time period 








Table/graphic displaying total and disaggregated costs for 
each time period (pharmacy/physician visit, in/out/home-
patient care). 








Based on the results. 
Design aspects, off-label use, adherence assumptions, 




Supplementary table 2-Overview of the disaggregated and total events 
2017 2018 2019 2020 2021 Total 
Number of COPD exacerbations 
Baseline scenario 349,389 354,333 359,277 364,221 369,165 1796385 
Switch scenario 346,004 350,900 355,796 360,692 365,588 1778980 
Difference -3,385 -3,433 -3,481 -3,529 -3,577 -17405
Number of events related to poor diabetes control (included as scenario, excluded from the base case) 
Baseline scenario 5,106 5,178 5,250 5,322 5,395 26251 
Switch scenario 4,602 4,667 4,732 4,797 4,862 23660 
Difference -504 -511 -518 -525 -532 -2591
Number of LRTI/pneumonia events 
Baseline scenario 25,097 25,452 25,807 26,162 26,517 129034 
Switch scenario 22,766 23,088 23,410 23,732 24,054 117050 
Difference -2,331 -2,364 -2,397 -2,430 -2,463 -11984
40
Supplementary table 3-Overview of the disaggregated annual and total costs and savings in euros 
2017 2018 2019 2020 2021 Total 
Baseline scenario costs 
TOTAL     € 592,330,427    € 595,448,061      € 598,578,920  € 601,724,745   € 604,887,159 € 2,992,969,312 
Cost of treatment  € 173,026,189  € 170,210,387  € 167,407,810  € 164,620,198   € 161,849,175 € 837,113,759 
Costs associated with exacerbations  € 377,636,748  € 382,980,562  € 388,324,375 € 393,668,189   € 399,012,002 € 1,941,621,876 
Costs associated with pneumonia  € 41,667,490  € 42,257,113  € 42,846,735  € 43,436,358   € 44,025,981 € 214,233,677 
Switch scenario costs 
TOTAL      € 575,472,232  € 578,635,160  € 581,810,599      € 585,000,196  € 588,205,489 € 2,909,123,676 
Cost of treatment  € 163,696,615      € 161,032,641      € 158,381,178      € 155,743,874      € 153,122,265 € 791,976,574 
Costs associated with exacerbations    € 373,977,914    € 379,269,953     € 384,561,991     € 389,854,030   € 395,146,069 € 1,922,809,956 
 Costs associated with pneumonia  € 37,797,703  € 38,332,566  € 38,867,429  € 39,402,292   € 39,937,155 € 194,337,146 
Cost difference 
TOTAL   -€ 16,858,195      -€ 16,812,902 -€ 16,768,322  -€ 16,724,549  -€ 16,681,670 -€ 83,845,636 
Costs of treatment   -€ 9,329,574  -€ 9,177,746   -€ 9,026,631   -€ 8,876,323  -€ 8,726,910 -€ 45,137,185 
Costs associated with exacerbations  -€ 3,658,834   -€ 3,710,609   -€ 3,762,384   -€ 3,814,159  -€ 3,865,934 -€ 18,811,919 
Costs associated with pneumonia  -€ 3,869,786   -€ 3,924,546   -€ 3,979,306   -€ 4,034,066  -€ 4,088,826 -€ 19,896,532 
41
